Large Molecule

From gene therapies to infectious disease vaccines, biologics are an exciting area of pharmaceuticals. This section offers content related to protein-based drugs manufactured using living cells.

Articles

Shutterstock 239423872
Shutterstock 239423872
Shutterstock 239423872
Shutterstock 239423872
Shutterstock 239423872

Shedding stigmas

Modern-day medications might finally mean obesity can be viewed as treatable
Shutterstock 1907619631
Shutterstock 1907619631
Shutterstock 1907619631
Shutterstock 1907619631
Shutterstock 1907619631

Optimizing mRNA therapeutics

Novel techniques for mRNA delivery, capping and more will be key to producing more effective vaccines
Image
Image
Image
Image
Image

Surrendering to the pharma magic

The science of ADCs makes for an incredible show
How Mass Spectrometer Works
How Mass Spectrometer Works
How Mass Spectrometer Works
How Mass Spectrometer Works
How Mass Spectrometer Works

Mass spectrometry: Optimizing biopharma manufacturing

Speed and precision make MS the first choice for the real-time monitoring of fermentation and cell culture off-gas
Screen Shot 2023 06 14 At 12 13 06 Pm
Screen Shot 2023 06 14 At 12 13 06 Pm
Screen Shot 2023 06 14 At 12 13 06 Pm
Screen Shot 2023 06 14 At 12 13 06 Pm
Screen Shot 2023 06 14 At 12 13 06 Pm

Spring pharma happenings: PDA’s Annual Meeting 2023

Through discussions that focused on innovative operational approaches as well as powerful patient-hosted sessions, the show sought to remind manufacturers to keep a patient-focused...
Pm22 Hero 854x480 Act1 Cover Story
Pm22 Hero 854x480 Act1 Cover Story
Pm22 Hero 854x480 Act1 Cover Story
Pm22 Hero 854x480 Act1 Cover Story
Pm22 Hero 854x480 Act1 Cover Story

The great reappearing act: ADCs' triumphant return

In our three-part series, we cover the trajectory of cancer-fighting ADCs in the pharma industry, including the modality’s history, obstacles and success stories
Microsoft Teams Image (1)
Microsoft Teams Image (1)
Microsoft Teams Image (1)
Microsoft Teams Image (1)
Microsoft Teams Image (1)

The great reappearing act: ADCs light up the stage

In the third and final part of our series on antibody-drug conjugates, we discuss the recent market buzz and the rise of new conjugated modalities.
Pm22 Hero 854x480 Act2 Cover Story
Pm22 Hero 854x480 Act2 Cover Story
Pm22 Hero 854x480 Act2 Cover Story
Pm22 Hero 854x480 Act2 Cover Story
Pm22 Hero 854x480 Act2 Cover Story

The great reappearing act: ADCs' new bag of tricks

In Act 2 of our series on antibody-drug conjugates, we cover improved linker and payload technology
Shutterstock 1978782344
Shutterstock 1978782344
Shutterstock 1978782344
Shutterstock 1978782344
Shutterstock 1978782344

Beyond empty and full

The field is in need of more detailed product understanding to increase product safety without sacrificing efficacy
Screen Shot 2023 03 09 At 1 46 33 Pm
Screen Shot 2023 03 09 At 1 46 33 Pm
Screen Shot 2023 03 09 At 1 46 33 Pm
Screen Shot 2023 03 09 At 1 46 33 Pm
Screen Shot 2023 03 09 At 1 46 33 Pm

The next chapter in cell and gene therapy

ATW 2023 celebrated a record-breaking year of approvals, with an eye on new realities
PM2206-HERO-575x327-Culture
PM2206-HERO-575x327-Culture
PM2206-HERO-575x327-Culture
PM2206-HERO-575x327-Culture
PM2206-HERO-575x327-Culture

mRNA boom: A double-edged sword

Did short-term solutions for COVID-19 stifle long-term mRNA success?
shutterstock-2156441753
shutterstock-2156441753
shutterstock-2156441753
shutterstock-2156441753
shutterstock-2156441753

A lot on its plate

Lacking an established workforce, the nascent cell and gene therapy industry must grow its own talent
IMG-5103-copy
IMG-5103-copy
IMG-5103-copy
IMG-5103-copy
IMG-5103-copy

Now touring: Cell and gene therapy

Germfree Labs’ city-by-city educational series addresses challenges and solutions in CGT manufacturing
PM2203-HERO-880x500-Development-copy
PM2203-HERO-880x500-Development-copy
PM2203-HERO-880x500-Development-copy
PM2203-HERO-880x500-Development-copy
PM2203-HERO-880x500-Development-copy

What’s next in adoptive cell therapy

Overcoming new manufacturing challenges as the cellular immunotherapy landscape expands
PM2202-HERO-575x327-Automation-copy
PM2202-HERO-575x327-Automation-copy
PM2202-HERO-575x327-Automation-copy
PM2202-HERO-575x327-Automation-copy
PM2202-HERO-575x327-Automation-copy

Biopharma 4.0: Industrializing biology

The rapid increase in automated solutions is radically reforming the way scientists discover and develop new therapies